IGF2BP1-IN-1
Based on 1 Customer Validation
IGF2BP1-IN-1, a Cucurbitacin B (HY-N0416) derivative, is a potent IGF2BP1 inhibitor (KD = 2.88 nM). IGF2BP1-IN-1 binds directly to IGF2BP1, thereby inducing tumor cell cycle arrest, increasing apoptosis, and reducing autophagy. IGF2BP1-IN-1 can be used in research on NSLSC, colon, breast, liver, ovarian, pancreatic, and cervical cancers.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 3029447-08-0
- Formula: C42H52FN3O10
- Molecular Weight:777.87
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Biological Activity
Description
IC50 & Target
|
Bcl-xL |
Bcl-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.009 μM
Compound: A11
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| A549 | IC50 |
5 nM
Compound: A11
|
Antiproliferative activity against wild type human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against wild type human A549 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| A549 | IC50 |
92 nM
Compound: A11
|
Antiproliferative activity against human A549 cells with IGF2BP1 knockdown assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells with IGF2BP1 knockdown assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| BXPC-3 | IC50 |
0.018 μM
Compound: A11
|
Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| CFPAC-1 | IC50 |
0.037 μM
Compound: A11
|
Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human CFPAC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| HCT-116 | IC50 |
0.034 μM
Compound: A11
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| HeLa | IC50 |
0.015 μM
Compound: A11
|
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| HepG2 | IC50 |
0.08 μM
Compound: A11
|
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| L02 | IC50 |
0.1 μM
Compound: A11
|
Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human L02 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| MCF7 | IC50 |
0.056 μM
Compound: A11
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| MDA-MB-231 | IC50 |
0.049 μM
Compound: A11
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| PANC-1 | IC50 |
0.088 μM
Compound: A11
|
Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
| SK-OV-3 | IC50 |
0.054 μM
Compound: A11
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 37681508] |
In Vitro
IGF2BP1-IN-1 (compound A11) (72 h) exhibits potent and selective inhibition of cell proliferation in human non-small cell lung cancer cells (A549) (IC50 = 0.009 μM; SI = 11.11). IGF2BP1-IN-1 significantly inhibits the proliferation of various cancer cell lines, including HCT-116 (IC50 = 0.080 μM), MDA-MB-231 (IC50 = 0.049 μM), MCF-7 (IC50 = 0.056 μM), SK-OC-3 (IC50 = 0.054 μM), HeLa (IC50 = 0.015 μM), HepG-2 (IC50 = 0.080 μM), BXPC-3 (IC50 = 0.018 μM), PANC-1 (IC50 = 0.088 μM), and CFPAC-1 (IC50 = 0.037 μM). IGF2BP1-IN-1 shows weaker inhibitory activity against the L02 cell line (IC50 = 0.100 μM)[1].
IGF2BP1-IN-1 (0.1-0.5 μM; 48 h) significantly induces apoptosis in human non-small cell lung cancer cells (A549) in a dose-dependent manner. IGF2BP1-IN-1 significantly inhibits autophagy in human non-small cell lung cancer cells (A549) in a dose-dependent manner[1].
IGF2BP1-IN-1 (0.1-0.5 μM; 24 h) induces cell cycle arrest at the G2/M phase in human non-small cell lung cancer cells (A549)[1].
IGF2BP1-IN-1 (0.625-10 μM) binds directly and irreversibly to recombinant IGF2BP1 in vitro with extremely high affinity (KD = 2.88 nM)[1].
IGF2BP1-IN-1 (1 μM; 2 h) binds directly to endogenous IGF2BP1 and increases its thermal stability in human non-small cell lung cancer (A549) cells[1].
IGF2BP1-IN-1 (0.1-1.0 μM; 48 h) dose-dependently inhibits the expression of the downstream protein c-MYC, anti-apoptotic proteins Bcl-2 and Bcl-xl, and cell cycle proteins CDK4 and Cyclin D1, while inducing PARP cleavage in human non-small cell lung cancer (A549) cells[1].
The antiproliferative activity of IGF2BP1-IN-1 (72 h) is significantly reduced in human non-small cell lung cancer (A549) cells where IGF2BP1 expression has been knocked down via siRNA (IC50 value increased from 0.005 μM to 0.092 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 cells
-
Concentration:0.1 μM, 0.2 μM, 0.5 μM
-
Incubation Time:24 h
-
Result:Led to a significant accumulation of A549 cells in the G2/M phase, inducing cell cycle arrest.
-
Cell Line:A549 cells
-
Concentration:0.1 μM, 0.2 μM, 0.5 μM
-
Incubation Time:48 h
-
Result:Significantly and dose-dependently induced apoptosis in A549 cells, especially remarkably increasing the proportion of late apoptotic cells.
-
Cell Line:A549 cells
-
Concentration:0.1 μM, 0.2 μM, 0.5 μM
-
Incubation Time:48 h
-
Result:Significantly elevated the LC3II to LC3I ratio and dose-dependently increased the expression level of p62 protein without notably affecting Beclin-1 expression, indicating the blockade of the autophagic degradation phase.
-
Cell Line:A549 cells
-
Concentration:0.1 μM, 0.2 μM, 0.5 μM, 1 μM
-
Incubation Time:48 h
-
Result:Dose-dependently inhibited the expression of c-MYC, Bcl-2, Bcl-xl, CDK4, and Cyclin D1 proteins, and promoted the cleavage of PARP, without altering the total level of IGF2BP1 protein itself.
In Vivo
IGF2BP1-IN-1 (0.5 mg/kg; i.p.; once daily for the first 6 days, followed by every other day; for 21-23 days) significantly inhibits tumor growth in a BALB/c male nude mouse xenograft model subcutaneously inoculated with A549 cells, without inducing significant changes in body weight or toxic side effects such as ascites. IGF2BP1-IN-1 significantly improves immunohistochemistry (IHC) and H&E staining scores and increased the expression level of the apoptosis-related marker TUNEL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Naive female C57BL/6J mice, without tumor induction[1]
-
Dosage:0.75 mg/kg
-
Administration:i.p., once daily, for 14 days
-
Result:Demonstrated good biosafety, showing no induction of weight loss or mortality in mice.
-
Animal Model:BALB/c nude mice (male, 14-17 g) were subcutaneously injected of 1 × 107 A549 cells[1]
-
Dosage:0.5 mg/kg
-
Administration:i.p., once daily for the first 6 days, followed by every other day; for 21-23 days
-
Result:Extremely significantly suppressed the volumetric expansion and weight gain of the A549 xenograft tumors in nude mice.
Achieved a remarkably high tumor growth inhibition (TGI) rate of 80%.
Demonstrated good biosafety, showing no induction of weight loss in mice and no toxic side effects.
Markedly increased proportion of cells exhibiting nuclear pyknosis and vacuolation in the treated tumor tissues.
Downregulated the expression level of Ki-67, a marker reflecting cellular proliferative activity in the tumor tissues.
Elevated the positive expression level of TUNEL, an indicator of DNA fragmentation and cell apoptosis in the tumor tissues.
Chemical Information
-
CAS No. 3029447-08-0
-
Appearance Solid
-
Molecular Weight 777.87
-
Formula C42H52FN3O10
-
Color White to off-white
-
SMILES
C[C@]12[C@@]3([H])[C@]([C@@]4([H])C(C(C)(C([C@H](C4)OC(CN5C(N(C6=CC=C(C=C6)F)C=N5)=O)=O)=O)C)=CC3)(C(C[C@@]1([C@@]([C@@H](C2)O)([H])[C@@](C)(O)C(/C=C/C(C)(C)OC(C)=O)=O)C)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (128.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2856 mL | 6.4278 mL | 12.8556 mL | 32.1390 mL |
| 5 mM | 0.2571 mL | 1.2856 mL | 2.5711 mL | 6.4278 mL | |
| 10 mM | 0.1286 mL | 0.6428 mL | 1.2856 mL | 3.2139 mL | |
| 15 mM | 0.0857 mL | 0.4285 mL | 0.8570 mL | 2.1426 mL | |
| 20 mM | 0.0643 mL | 0.3214 mL | 0.6428 mL | 1.6070 mL | |
| 25 mM | 0.0514 mL | 0.2571 mL | 0.5142 mL | 1.2856 mL | |
| 30 mM | 0.0429 mL | 0.2143 mL | 0.4285 mL | 1.0713 mL | |
| 40 mM | 0.0321 mL | 0.1607 mL | 0.3214 mL | 0.8035 mL | |
| 50 mM | 0.0257 mL | 0.1286 mL | 0.2571 mL | 0.6428 mL | |
| 60 mM | 0.0214 mL | 0.1071 mL | 0.2143 mL | 0.5357 mL | |
| 80 mM | 0.0161 mL | 0.0803 mL | 0.1607 mL | 0.4017 mL | |
| 100 mM | 0.0129 mL | 0.0643 mL | 0.1286 mL | 0.3214 mL |